321 related articles for article (PubMed ID: 35720417)
21. Cutting edge: TIGIT has T cell-intrinsic inhibitory functions.
Joller N; Hafler JP; Brynedal B; Kassam N; Spoerl S; Levin SD; Sharpe AH; Kuchroo VK
J Immunol; 2011 Feb; 186(3):1338-42. PubMed ID: 21199897
[TBL] [Abstract][Full Text] [Related]
22. Anti-human-TIGIT agonistic antibody ameliorates autoimmune diseases by inhibiting Tfh and Tph cells and enhancing Treg cells.
Kojima M; Suzuki K; Takeshita M; Ohyagi M; Iizuka M; Yamane H; Koga K; Kouro T; Kassai Y; Yoshihara T; Adachi R; Hashikami K; Ota Y; Yoshimoto K; Kaneko Y; Morita R; Yoshimura A; Takeuchi T
Commun Biol; 2023 May; 6(1):500. PubMed ID: 37161050
[TBL] [Abstract][Full Text] [Related]
23. TIGIT, the Next Step Towards Successful Combination Immune Checkpoint Therapy in Cancer.
Ge Z; Peppelenbosch MP; Sprengers D; Kwekkeboom J
Front Immunol; 2021; 12():699895. PubMed ID: 34367161
[TBL] [Abstract][Full Text] [Related]
24. Alteration of CD226/TIGIT immune checkpoint on T cells in the pathogenesis of primary Sjögren's syndrome.
Deng C; Chen Y; Li W; Peng L; Luo X; Peng Y; Zhao L; Wu Q; Zhang W; Zhang X; Fei Y
J Autoimmun; 2020 Sep; 113():102485. PubMed ID: 32466852
[TBL] [Abstract][Full Text] [Related]
25. T-cell immunoglobulin and ITIM domain, as a potential immune checkpoint target for immunotherapy of colorectal cancer.
Fathi M; Pustokhina I; Kuznetsov SV; Khayrullin M; Hojjat-Farsangi M; Karpisheh V; Jalili A; Jadidi-Niaragh F
IUBMB Life; 2021 May; 73(5):726-738. PubMed ID: 33686787
[TBL] [Abstract][Full Text] [Related]
26. Recent Advances of Immune Checkpoint Inhibition and Potential for (Combined) TIGIT Blockade as a New Strategy for Malignant Pleural Mesothelioma.
Rovers S; Janssens A; Raskin J; Pauwels P; van Meerbeeck JP; Smits E; Marcq E
Biomedicines; 2022 Mar; 10(3):. PubMed ID: 35327475
[TBL] [Abstract][Full Text] [Related]
27. Treatment of murine lupus with TIGIT-Ig.
Liu S; Sun L; Wang C; Cui Y; Ling Y; Li T; Lin F; Fu W; Ding M; Zhang S; Lei C; Hu S
Clin Immunol; 2019 Jun; 203():72-80. PubMed ID: 31005675
[TBL] [Abstract][Full Text] [Related]
28. CD155/TIGIT, a novel immune checkpoint in human cancers (Review).
Liu L; You X; Han S; Sun Y; Zhang J; Zhang Y
Oncol Rep; 2021 Mar; 45(3):835-845. PubMed ID: 33469677
[TBL] [Abstract][Full Text] [Related]
29. T-Cell Immunoglobulin and ITIM Domain (TIGIT) Associates with CD8+ T-Cell Exhaustion and Poor Clinical Outcome in AML Patients.
Kong Y; Zhu L; Schell TD; Zhang J; Claxton DF; Ehmann WC; Rybka WB; George MR; Zeng H; Zheng H
Clin Cancer Res; 2016 Jun; 22(12):3057-66. PubMed ID: 26763253
[TBL] [Abstract][Full Text] [Related]
30. A Systematic Review and Meta-Analysis on the Significance of TIGIT in Solid Cancers: Dual TIGIT/PD-1 Blockade to Overcome Immune-Resistance in Solid Cancers.
Hosseinkhani N; Shadbad MA; Asghari Jafarabadi M; Karim Ahangar N; Asadzadeh Z; Mohammadi SM; Lotfinejad P; Alizadeh N; Brunetti O; Fasano R; Silvestris N; Baradaran B
Int J Mol Sci; 2021 Sep; 22(19):. PubMed ID: 34638729
[TBL] [Abstract][Full Text] [Related]
31. Effective Anti-tumor Response by TIGIT Blockade Associated With FcγR Engagement and Myeloid Cell Activation.
Han JH; Cai M; Grein J; Perera S; Wang H; Bigler M; Ueda R; Rosahl TW; Pinheiro E; LaFace D; Seghezzi W; Williams SMG
Front Immunol; 2020; 11():573405. PubMed ID: 33117369
[TBL] [Abstract][Full Text] [Related]
32. The immune checkpoint TIGIT is upregulated on T cells during bacterial infection and is a potential target for immunotherapy.
McCulloch TR; Rossi GR; Miranda-Hernandez S; Valencia-Hernandez AM; Alim L; Belle CJ; Krause A; Zacchi LF; Lam PY; Nakamura K; Kupz A; Wells TJ; Souza-Fonseca-Guimaraes F
Immunol Cell Biol; 2024 Jun; ():. PubMed ID: 38873699
[TBL] [Abstract][Full Text] [Related]
33. TIGIT expression levels on human NK cells correlate with functional heterogeneity among healthy individuals.
Wang F; Hou H; Wu S; Tang Q; Liu W; Huang M; Yin B; Huang J; Mao L; Lu Y; Sun Z
Eur J Immunol; 2015 Oct; 45(10):2886-97. PubMed ID: 26171588
[TBL] [Abstract][Full Text] [Related]
34. A TIGIT-based chimeric co-stimulatory switch receptor improves T-cell anti-tumor function.
Hoogi S; Eisenberg V; Mayer S; Shamul A; Barliya T; Cohen CJ
J Immunother Cancer; 2019 Sep; 7(1):243. PubMed ID: 31500665
[TBL] [Abstract][Full Text] [Related]
35. Development of Anti-human T Cell Immunoreceptor with Ig and ITIM Domains (TIGIT) Monoclonal Antibodies for Flow Cytometry.
Takei J; Asano T; Nanamiya R; Nakamura T; Yanaka M; Hosono H; Tanaka T; Sano M; Kaneko MK; Harada H; Kato Y
Monoclon Antib Immunodiagn Immunother; 2021 Apr; 40(2):71-75. PubMed ID: 33900817
[TBL] [Abstract][Full Text] [Related]
36. Nonoverlapping roles of PD-1 and FoxP3 in maintaining immune tolerance in a novel autoimmune pancreatitis mouse model.
Zhang B; Chikuma S; Hori S; Fagarasan S; Honjo T
Proc Natl Acad Sci U S A; 2016 Jul; 113(30):8490-5. PubMed ID: 27410049
[TBL] [Abstract][Full Text] [Related]
37. TIGIT overexpression diminishes the function of CD4 T cells and ameliorates the severity of rheumatoid arthritis in mouse models.
Zhao W; Dong Y; Wu C; Ma Y; Jin Y; Ji Y
Exp Cell Res; 2016 Jan; 340(1):132-8. PubMed ID: 26683997
[TBL] [Abstract][Full Text] [Related]
38. Update in TIGIT Immune-Checkpoint Role in Cancer.
Annese T; Tamma R; Ribatti D
Front Oncol; 2022; 12():871085. PubMed ID: 35656508
[TBL] [Abstract][Full Text] [Related]
39. TIGIT enhances CD4
Chen F; Xu Y; Chen Y; Shan S
Cancer Med; 2020 May; 9(10):3584-3591. PubMed ID: 32212317
[TBL] [Abstract][Full Text] [Related]
40. TIGIT-Fc alleviates acute graft-versus-host disease by suppressing CTL activation via promoting the generation of immunoregulatory dendritic cells.
Zhang D; Hu W; Xie J; Zhang Y; Zhou B; Liu X; Zhang Y; Su Y; Jin B; Guo S; Zhuang R
Biochim Biophys Acta Mol Basis Dis; 2018 Sep; 1864(9 Pt B):3085-3098. PubMed ID: 29960041
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
